These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8293297)

  • 1. Inositol treatment raises CSF inositol levels.
    Levine J; Rapaport A; Lev L; Bersudsky Y; Kofman O; Belmaker RH; Shapiro J; Agam G
    Brain Res; 1993 Nov; 627(1):168-70. PubMed ID: 8293297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia.
    Levine J; Goldberger I; Rapaport A; Schwartz M; Schield C; Elizur A; Belmaker RH; Shapiro J; Agam G
    Eur Neuropsychopharmacol; 1994 Dec; 4(4):487-90. PubMed ID: 7894259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gas chromatographic-mass spectrometric determination of myo-inositol in human cerebrospinal fluid.
    Swahn CG
    J Neurochem; 1985 Aug; 45(2):331-4. PubMed ID: 4009166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF inositol does not predict antidepressant response to inositol. Short communication.
    Levine J; Kurtzman L; Rapoport A; Zimmerman J; Bersudsky Y; Shapiro J; Belmaker RH; Agam G
    J Neural Transm (Vienna); 1996; 103(12):1457-62. PubMed ID: 9029413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
    Croze ML; Soulage CO
    Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inositol treatment in psychiatry.
    Benjamin J; Agam G; Levine J; Bersudsky Y; Kofman O; Belmaker RH
    Psychopharmacol Bull; 1995; 31(1):167-75. PubMed ID: 7675981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.
    Plitman E; Chavez S; Nakajima S; Iwata Y; Chung JK; Caravaggio F; Kim J; Alshehri Y; Chakravarty MM; De Luca V; Remington G; Gerretsen P; Graff-Guerrero A
    Psychiatry Res Neuroimaging; 2018 Mar; 273():16-24. PubMed ID: 29414127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral maternal inositol supplementation does not increase rat conceptus inositol levels.
    Lauden A; Kofman O; Sobolev Y; Agam G
    Isr J Psychiatry Relat Sci; 1997; 34(4):262-4. PubMed ID: 9409082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid.
    Shetty HU; Schapiro MB; Holloway HW; Rapoport SI
    J Clin Invest; 1995 Feb; 95(2):542-6. PubMed ID: 7860736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated myo-inositol concentrations in cerebrospinal fluid of neonates and of patients with an impaired state of consciousness.
    Lepkifker E; Lewin LM
    Biomedicine; 1976 Dec; 25(10):368-71. PubMed ID: 1016679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inositol in the cerebrospinal fluid, plasma and erythrocytes in spinal pain syndromes].
    Maciejek Z; Chmielewski H; Lutz W; Niezgodzińska A
    Neurol Neurochir Pol; 1984; 18(2):125-30. PubMed ID: 6237272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haloperidol induced CSF protein variations in schizophrenic patients: as studied by two-dimensional electrophoresis.
    Johnson G; Brane D; van Kammen DP; Gurklis J; Peters JL; Perel JM; Ghanbari HA; Merril CR
    Appl Theor Electrophor; 1992; 3(1):21-6. PubMed ID: 1599960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myo-inositol transport in the central nervous system.
    Spector R; Lorenzo AV
    Am J Physiol; 1975 May; 228(5):1510-18. PubMed ID: 1130554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inositol in the cerebrospinal fluid in various nervous system diseases].
    Maciejek Z; Lisiewicz J; Lutz W; Kochanowski J
    Neurol Neurochir Pol; 1981; 15(2):155-9. PubMed ID: 7266753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF copper concentrations in chronic schizophrenia.
    Shore D; Potkin SG; Weinberger DR; Torrey EF; Henkin RI; Agarwal RP; Gillin JC; Wyatt RJ
    Am J Psychiatry; 1983 Jun; 140(6):754-7. PubMed ID: 6133465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher cerebrospinal fluid angiotensin-converting enzyme levels in neuroleptic-treated than in drug-free patients with schizophrenia.
    Wahlbeck K; Ahokas A; Miettinen K; Nikkilä H; Rimón R
    Schizophr Bull; 1998; 24(3):391-7. PubMed ID: 9718631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assay of myo-inositol in cerebrospinal fluid and plasma by chemical ionization mass spectrometry of the hexaacetate derivative.
    Shetty HU; Holloway HW
    Biol Mass Spectrom; 1994 Jul; 23(7):440-4. PubMed ID: 8068740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that a proconvulsant action of lithium is mediated by inhibition of myo-inositol phosphatase in mouse brain.
    Tricklebank MD; Singh L; Jackson A; Oles RJ
    Brain Res; 1991 Aug; 558(1):145-8. PubMed ID: 1657311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication].
    Chen YF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1984 Oct; 17(5):273-7. PubMed ID: 6085683
    [No Abstract]   [Full Text] [Related]  

  • 20. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies.
    Kim H; McGrath BM; Silverstone PH
    Hum Psychopharmacol; 2005 Jul; 20(5):309-26. PubMed ID: 15880397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.